- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Kalveer Flora, MPharm: Coordinating With Providers on Biosimilar Switching
Kalveer Flora, MPharm, London North West University Healthcare National Health Service (NHS) Trust, discusses how she coordinates with providers on biosimilar switching programs.
Transcript
In order to maintain sustainability and make sure that the switch goes well, what I like to do is organize regular catch-ups and touch base just to see how the homecare providers are doing in terms of switching.
What we do is, I usually switch patients in batches, so patients who have come to the clinic and have been told that they’ll be changing. I communicate this information to the homecare providers so that they know which patients they will be delivering the biosimilar to.
It’s important that homecare providers are aware, and also that they have enough medicines, because the last thing that I want is to switch a patient and there to be a problem with procuring the biosimilar for them. So it’s just really about organization and communication.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
